Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts

SP Bhatt, KF Rabe, NA Hanania… - … England Journal of …, 2023 - Mass Medical Soc
Background In some patients with chronic obstructive pulmonary disease (COPD), type 2
inflammation may increase exacerbation risk and may be indicated by elevated blood …

2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD

J Bourbeau, M Bhutani, P Hernandez, SD Aaron… - Chest, 2023 - Elsevier
Chronic obstructive pulmonary disease patient care must include confirming a diagnosis
with postbronchodilator spirometry. Because of the clinical heterogeneity and the reality that …

[HTML][HTML] Impact of acute exacerbations of COPD on patients' health status beyond pulmonary function: A scoping review

A Machado, M Barusso, J De Brandt, K Quadflieg… - Pulmonology, 2023 - Elsevier
This scoping review summarized the evidence regarding the impact of acute exacerbations
of COPD (AECOPD) on patients' health status beyond pulmonary function. PubMed …

Icenticaftor, a CFTR potentiator, in COPD: a multicenter, parallel-group, double-blind clinical trial

FJ Martinez, GJ Criner, C Gessner, M Jandl… - American Journal of …, 2023 - atsjournals.org
Rationale: CFTR (cystic fibrosis transmembrane conductance regulator) dysfunction is
associated with mucus accumulation and worsening chronic obstructive pulmonary disease …

[HTML][HTML] Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation …

MFA Chaudhary, EA Hoffman, J Guo… - The Lancet Digital …, 2023 - thelancet.com
Background Quantitative CT is becoming increasingly common for the characterisation of
lung disease; however, its added potential as a clinical tool for predicting severe …

Clinical concepts for triple therapy use in patients with COPD: a Delphi consensus

M Miravitlles, S Acharya, B Aggarwal… - … Journal of Chronic …, 2023 - Taylor & Francis
Purpose Role of triple therapy in chronic obstructive pulmonary disease (COPD)
management is supported by growing evidence, but consensus is lacking on various …

[HTML][HTML] Cough in chronic lung disease: a state of the art review

B Hirons, K Rhatigan, H Kesavan… - Journal of Thoracic …, 2023 - ncbi.nlm.nih.gov
Chronic cough (CC;≥ 8 weeks in duration) is a common and burdensome feature of
respiratory diseases. The understanding of cough has progressed significantly in recent …

[HTML][HTML] Implementing an evidence-based COPD hospital discharge protocol: a narrative review and expert recommendations

M Miravitlles, M Bhutani, JR Hurst, FME Franssen… - Advances in …, 2023 - Springer
Discharge bundles, comprising evidence-based practices to be implemented prior to
discharge, aim to optimise patient outcomes. They have been recommended to address …

Clinical phenotypes of COPD and their impact on quality of life: A cross-sectional study

J Anandan, DP Dwivedi, V Govindaraj - Respiratory Medicine, 2023 - Elsevier
Abstract Background A Chronic Obstructive Pulmonary Disease (COPD) phenotype is a
single or group of disease characteristics that describe differences between individuals …

A double-blind, randomized, placebo-controlled trial of long-term doxycycline therapy on exacerbation rate in patients with stable chronic obstructive pulmonary …

JP Allinson, BH Vlies, SE Brill, M Law… - American Journal of …, 2023 - atsjournals.org
Rationale: Chronic obstructive pulmonary disease (COPD) exacerbations are a major cause
of morbidity and mortality, and preventing them is a key treatment target. Long-term …